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Purpose: Eicosanoids with vasodilating and angiogenic properties have been postulated to be effective therapies for critical
leg ischemia (CLI) secondary to atherosclerotic peripheral arterial disease. The ability to deliver active drug to the site of
action at adequate doses for sufficient duration has been a major limitation in the clinical development of such therapies.
Lipo-ecraprost is a lipid-encapsulated prostaglandin E1 prodrug with the potential to deliver active prostaglandin to the
site of critical arterial ischemia. The current trial was designed to test the hypothesis that lipo-ecraprost would improve
amputation-free survival in patients with CLI who had no revascularization options.
Methods: The study was randomized, multicenter, double blind, and placebo controlled. Patients who met clinical and
hemodynamic criteria were randomized to receive placebo or lipo-ecraprost (60 g) administered intravenously on each
of 5 days per week, for a total of 8 weeks. The study’s primary endpoint was the rate of a composite end point of death
or amputation above the level of the ankle at 180 days (6 months).
Results:The study was terminated on a recommendation from theData and SafetyMonitoring Board after the completion
of a protocol-specified interim analysis for futility. At the time of termination, 383 of the planned 560 patients had been
randomized, of which 379 received at least one dose of study medication and thus were included in the intention-to-treat
population. Twenty-three patients were lost to follow-up and were not available for 6-month assessments. At 6 months
of follow-up, there were 23 amputations in the 177 patients who received placebo, and 29 amputations in the 179
patients randomized to lipo-ecraprost. At 6 months, 10 deaths had occurred in the placebo group and 18 deaths had
occurred in the lipo-ecraprost arm. Changes in lower-extremity hemodynamics over the 6-month study period did not
differ between the placebo and lipo-ecraprost treatment arms.
Conclusion: Intensive treatment with lipo-ecraprost failed to modify the 6-month amputation rate in patients with CLI
who were not candidates for revascularization. (J Vasc Surg 2006;43:752-9.)Peripheral arterial disease is the lower-extremity mani-
festation of systemic atherosclerotic disease.1 Critical leg
ischemia (CLI), manifested as either ischemic pain at rest or
ischemic ulcers or gangrene,2 results when the blood flow
limitation becomes severe enough to compromise tissue
viability. Conservative management, such as with analgesics
and local wound care, may allow for transient improve-
ment, but limb salvage ultimately depends on improving
circulation to the compromised tissue. Despite optimal
current therapies, durable limb salvage rates in patients who
are not candidates for revascularization are poor, and only
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75245% of patients are alive without a major amputation after 6
months.3 This in part reflects an estimated 20% 6-month
mortality secondary to lower-extremity complications and
systemic atherosclerotic disease.3
The theoretical basis for prostaglandin therapy in CLI
is well established. Prostaglandins of the E and prostacyclin
series may dilate important vascular beds, directly improv-
ing local blood flow.4 These prostaglandins also have an-
giogenic,4-6 anti-inflammatory,7 and antiplatelet7 effects in
model systems and patients. Prostaglandin E1 has been
shown to improve endothelial function in patients with
CLI,7,8 although these effects have not been consistently
observed.9 Clinically, use of prostaglandins has been ham-
pered by their very high systemic clearance (typical half-life
in minutes) and dose-limiting side effects.10,11 The inabil-
ity to deliver high prostaglandin concentrations to periph-
eral vascular beds may limit the beneficial local hemody-
namic actions of prostaglandin dosing.12 Therapeutic
administration of prostaglandins results in systemic vasodi-
lation with resultant hypotension and other related adverse
responses.10 Despite these limitations, results from several
trials have suggested that prostaglandins may have efficacy
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iloprost have been studied in double-blind trials and were
shown in some reports to decrease ulcer size and rest pain in
patients with CLI.10,13-15
Novel prostaglandin analogs and formulations have
been developed to improve targeted delivery to ischemic
tissues. For example, esters of prostaglandins can be hydro-
lyzed in serum and release an active prostaglandin over
time.16 Targeted delivery to the vascular wall and areas of
neovascularization may be enhanced by lipid encapsulation
of the prostaglandin.17 Lipo-ecraprost is a novel prepara-
tion of the prostaglandin E1 analog ecraprost (1-butyl-9-
oxobutory prostaglandin E1) in lipid microspheres (Circu-
lase, Mitsubishi Pharma Corp, Tokyo, Japan). Treatment
with ecraprost in a similar lipid preparation for 4 weeks
improved pain-free walking distance in patients with clau-
dication.18 A phase II trial of lipo-ecraprost for the treat-
ment of CLI demonstrated that the drug was well tolerated
and was associated with a decrease in the rate of amputa-
tions.19
Based on these concepts and data, the current trial
tested the hypothesis that 8-weeks of treatment with lipo-
ecraprost (60 g ecraprost per day, 5 days per week) would
decrease the rate of major amputations or death in patients
with CLI.
MATERIALS AND METHODS
Overview of trial design. The study was a multi-
center, randomized, double-blinded, placebo-controlled
trial designed to test the hypothesis that lipo-ecraprost
treatment would improve amputation-free survival in pa-
tients with CLI. The target population was patients with
atherosclerotic CLI who were not candidates for revascu-
larization. Patients were randomized, with stratification by
diabetic status within each study site, to receive placebo or
lipo-ecraprost (60 g ecraprost) administered intrave-
nously on each of five days per week for a total of 8 weeks
(maximum of 40 total doses). The study was approved by
the appropriate Institutional Review Boards, and all pa-
tients provided informed consent.
Patient inclusion/exclusion criteria. Patients were
eligible for randomization if they were aged40 years old,
were able to provide informed consent directly or through
an authorized representative, and had CLI clinically de-
fined by the presence of distal extremity pain at rest requir-
ing use of analgesics for at least 2 weeks or the presence of
peripheral ischemic ulcers or areas of gangrene. Addition-
ally, patients must have had hemodynamic evidence of CLI.
In the case of patients with rest pain only (Fontaine
stage III), CLI diagnosis required either a highest ankle
systolic pressure (posterior tibial or dorsalis pedis)50mm
Hg in the affected limb, toe systolic pressure30 mmHg,
or a pedal transcutaneous oxygen pressure (TcPO2) of30
mm Hg (with a limb/chest TcPO2 ratio 0.5). In the case
of patients with ulcers or gangrene (Fontaine stage IV), the
ankle and toe pressure cutoffs were 70 mm Hg and 50
mm Hg, respectively.For purposes of theses analyses, Fontaine stage was
determined from the index limb that was used for the
inclusion or exclusion assessment. For example, if the index
limb had rest pain and qualifying hemodynamics, but the
contralateral limb had an ulcer but nonqualifying hemody-
namics, the patient was considered Fontaine stage III ow-
ing to the uncertain etiology of the ulcer. Additionally,
patients must have exhausted all standard revascularization
options, and their peripheral arterial disease prognosis and
clinical status ruled out revascularization at the time of
randomization.
Patients were excluded from participation if:
● they had a previous major amputation above the level
of the ankle or if the investigator believed that a major
amputation would be required4weeks of the screen-
ing period.
● they had had a revascularization procedure 8 weeks
of treatment initiation or if the area of an individual
ulcer or area of gangrene was 20 cm2.
● they were on antihypertensive therapy that had been
changed within the previous 4 weeks or if they had
persistent or recurrent systolic blood pressure mea-
surements 90 mm Hg.
● they had clinical evidence of sepsis, end-stage renal
disease (creatinine clearance 20 mL/min), symp-
tomatic arrhythmias, advanced atrioventricular block,
severe heart failure (New York Heart Association class
III or IV), or had had a myocardial infarction 12
weeks of treatment initiation.
● their screening serum aspartate aminotransferase or
alanine aminotransferase exceeded three times the up-
per limit of normal, or if the serum bilirubin concen-
tration was 1.5 times the upper limit of normal.
● they had received another investigational drug of any
type or had received prostanoid therapy for peripheral
arterial disease 90 days of randomization.
Women were eligible to participate only if they had
been surgically sterilized, were at least 1 year postmeno-
pausal, or had been practicing adequate contraception for
at least 12 weeks before entering the study.
An investigator could categorize a patient as ineligible
if, in the opinion of the investigator, the patient had a
comorbid condition likely to interfere with the end-point
assessment or that compromised the patient’s safe partici-
pation in the study, or if the patient was thought to be
unreliable or uncooperative.
Outline of study procedures. After providing in-
formed consent, patients underwent a series of screening
procedures that were completed 10 days of randomiza-
tion. Screening included a medical history, physical exam-
ination, electrocardiogram (ECG), history of peripheral
vascular interventions (revascularizations and amputations),
clinical and hemodynamic assessment of the symptomatic
lower extremity, and routine blood chemistry and hematol-
ogy assays. Patients who met the inclusion/exclusion crite-
ria were randomized.
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a visual analog scale before receiving the first dose of the
study medication. Study medication was given intrave-
nously over approximately 10 minutes, and the patient’s
blood pressure and pulse were monitored. Patients contin-
ued to receive the study medication 5 days per week for 8
weeks. Adverse events were documented on each dosing
day. On day 5, an additional ECGwas performed at least 45
minutes after study medication dosing.
At the 8-week time point, patients underwent a physical
exam, repeat assessment of the ischemic limb (clinical as-
sessment and hemodynamic measurements), blood chem-
istry and hematology assessments, pain assessment on the
visual analog scale, and an ECG. Details of any amputation
or revascularization procedures were documented. Patients
were contacted monthly by telephone after the 8-week visit
through 1 year, and information concerning amputation or
revascularization procedures was obtained. At 6 and 12
months after randomization, the procedures conducted at
week 8 were repeated.
Study end points and statistical considerations.
The primary efficacy end point was the reduction in the
event rate, defined as the proportion of patients who un-
derwent a major amputation above the ankle or died180
days of the initial study treatment. Analyses were conducted
in which patients with unknown limb or mortality status
either were considered as treatment failures (assumed to
have had an amputation or died) in logistic regression
analyses or were censored at the time of last contact in
time-to-event analyses by using Kaplan-Meier method or
Cox regression models. The anticipated event rate in the
placebo group was 30% based on literature data,3 This 30%
event rate was estimated to be comprised of one third
deaths and two thirds amputations, with absolute rates of
10% and 20%, respectively.
The study was powered to detect a 60% reduction in
amputations owing to lipo-ecraprost, assuming the drug
had no affect on mortality, with projected active treatment
6-month event rates of 10% mortality, 8% amputation, or
18% for the composite. Based on an   0.05 and a power
of 90%, the study was designed to include 280 patients per
arm, or a total of 560 randomized subjects.
Analysis of the primary end point was by logistic regres-
sion assessing the effect of treatment on the event rate when
adjusted for the baseline characteristics of diabetic status,
Fontaine stage, and a history of revascularization. Other
analyses of the primary efficacy end point included time-to-
event by using the Kaplan-Meier method, Cox regression
models, and analysis stratified by investigational sites.
Secondary end points included analyses of 12-month
data, the proportion of patients who had a major amputa-
tion, all-cause mortality, the number of cardiovascular ad-
verse events, patients who had a revascularization during
the study period, patients who had complete ulcer healing,
resolution of pain at rest as assessed by patient response to
site investigator question, and change in hemodynamics.
Adverse events were compiled on a descriptive basis.Other study design elements. Conduct of the study
was overseen by a steering committee whose charter in-
cluded a commitment by the sponsor to publish the trial’s
results in a timely manner. An independent Data and Safety
Monitoring Board (DSMB) met quarterly to review study
progress and adverse events in an unblinded manner. Ad-
ditionally, the DSMB conducted a protocol-specified in-
terim analysis after 50% of the planned total number of
patients had completed the 6-month assessment. The in-
terim analysis included a guideline that would support a
recommendation for early termination if the conditional
probability for a positive study based on the primary end
point was 0.20. The stopping guidelines also included
possible termination for benefit or harm with an  
0.00005, resulting in an adjusted   0.0499 for final
analysis.
An independent Clinical Events Committee (CEC)
reviewed all adverse events. The CEC categorized events
as cardiovascular when angina, congestive heart failure,
myocardial infarction, stroke, transient ischemia, or acute
limb ischemia was determined to be the basis of the adverse
event by using prospective consensus criteria. The CEC
also reviewed all amputations and deaths to confirm the
accuracy of recorded data and compliance with end-point
definitions.
RESULTS
The study was terminated early by recommendation of
the DSMB after it had completed the protocol-specified
interim analysis. At the time the study was terminated, 383
patients had been randomized, of whom 379 had received
at least one dose of study medication and thus comprised
the intention-to-treat population.
The placebo and lipo-ecraprost–treated groups did not
differ with respect to baseline characteristics (Table I).
Hemodynamic assessments of the affected lower extremity
were consistent with the diagnosis of CLI (Table II). In the
Fontaine stage III patients enrolled on the basis of toe
pressures, the placebo group had a significantly lower mean
toe pressure than the lipo-ecraprost patients. Otherwise,
baseline hemodynamic measurements did not differ be-
tween the treatment groups. Approximately 63.7% and
54.0% of the patients assigned to the placebo and lipo-
ecraprost groups, respectively, received35 doses of study
medication. The distribution of study drug doses actually
received by patients in the two treatment groups was similar
(Table III).
After 6 months, 13 patients in the placebo arm and 10
patients in the lipo-ecraprost arm were unavailable for
end-point assessment. Of the remaining patients, 13.0%
(23 of 177) of the placebo-treated patients and 16.2% (29
of 179) of the patients receiving lipo-ecraprost had under-
gone a major amputation (Table IV). All amputations were
assessed by the CEC as secondary to complications of
ischemia, with untreatable infection the most common
indication. If patients who were recruited 8 weeks of the
early termination decision (ie, those who could not have
completed the protocol-intended therapy) were excluded,
)show
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6-months in the placebo (n  170) vs lipo-ecraprost (n 
172) groups, respectively. Analysis based only on patients
who received at least 20 doses of study medication sup-
ported the conclusion that lipo-ecraprost did not affect
amputation rates (data not shown).
Logistic regression analyses incorporating diabetes
status, Fontaine stage, and history of previous revascular-
ization confirmed the lack of significant impact of lipo-
ecraprost on event rates. Similarly, results from stratified
analyses based on study site or study country (United States
vs United Kingdom) did not suggest a beneficial effect of
Table I. Patient demographics (intention-to-treat populat
Placebo
N 190
Mean Age (yrs) (range) 69.7 (42.7-96
Gender (M/F) (% male) 130/60 (68
Race
White 133
Black 37
Hispanic 18
Asian 1
Other/unknown 1
Diabetes mellitus (%) 53.7
Fontaine stage III/IV (% stage IV) 91/99 (52
Table II. Qualifying baseline hemodynamic assessments
Fontaine stage III
Placebo Lipo-ecraprost
Ankle pressure 33.9  25.5 (27) 31.1  26.5 (28) 32.5 
Toe pressure 9.0  12.4 (48) 16.0  13.8 (51)* 12.6 
TcPO2 20.3  11.5 (16) 19.9  7.4 (8) 20.1 
TcPO2, Transcutaneous oxygen pressure.
Not all measurements were made on all patients, as only one qualifying mea
for randomization, and this value was used in the table. In the case of ankle pr
Values are mm Hg and are expressed as mean  standard deviation, with N
*P  .01 placebo vs lipo-ecraprost by t test.
Table III. Distribution of actual doses received by
patients in each treatment group
Total doses actually
received (%)
Placebo
(n 190) (%)
Lipo-ecraprost
(n  189) (%)
1-5 8 (4.2) 16 (8.5)
6-10 7 (3.7) 17 (9.0)
11-15 4 (2.1) 8 (4.2)
16-20 12 (6.3) 11 (5.8)
21-25 5 (2.6) 2 (1.1)
26-30 9 (4.7) 6 (3.2)
31-35 24 (12.6) 27 (14.3)
35 121 (63.7) 102 (54.0)
The numbers of patients (and the percentage of the treatment group in
parenthesis) receiving doses of study medication within each of the ranges
shown are indicated.lipo-ecraprost in any cohort.Mortality during the 6-month study period was 5.6%
and 10.1% in the placebo and lipo-ecraprost groups,
respectively (P  .123) (Table IV). Mortality was higher in
the Fontaine stage IV patients than in stage III patients,
independent of treatment arm (1.2% vs 9.6% in III vs IV in
the placebo group, and 7.2% vs 12.5% in III vs IV in the
lipo-ecraprost group, based on the full intention to treat
cohort). Thus, treatment with lipo-ecraprost did not
affect the number of major amputations, deaths, or the
composite end point of major amputation or death at
6 months (Table IV). Analyses in which patients unavail-
able at 6 months were set as treatment failures (vs simply
being considered lost to follow-up and censored from the
analysis) in the composite end point did not change the
conclusions.
Kaplan-Meier plots of the time to first major ampu-
Lipo-ecraprost All
189 379
69.7 (43.7-99.4) 69.7 (42.7-99.4)
127/62 (67) 257/122 (68)
127 260
42 79
15 33
4 5
1 2
59.3 56.4
87/102 (54) 178/201 (53)
Fontaine stage IV
Placebo Lipo-ecraprost All
(55) 51.8  41.3 (51) 44.9  26.1 (43) 48.6  35.1 (94)
(99) 23.5  18.1 (40) 20.8  19.1 (46) 22.0  18.6 (86)
(24) 12.3  9.6 (8) 16.3  9.0 (13) 14.8  9.2 (21)
ent of ankle pressure, toe pressure, or TcPO2 in the index limb was required
s, the highest value from either the dorsalis pedis or posterior tibial was used.
n in parentheses.
Table IV. Amputation and death at 180 days in the
intention to treat population
Event
Placebo
(n 177) (%)
Lipo-ecraprost
(n  179) (%)
Major amputation 23 (13.0) 29 (16.2)
Death 10 (5.6) 18 (10.1)
Composite (amputation
or death) 31 (17.5) 43 (24.0)
In assessing the composite endpoint, each patient could only be counted
once. Totals exclude the 23 patients for whom 6-month data were unavail-
able.ion)
.4)
)All
25.8
13.5
10.2
surem
essuretation (with patients censored at time of death or lost to
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lost to follow-up) confirmed the lack of significant dif-
ference between the treatment arms (Fig). The trend to
increased mortality associated with lipo-ecraprost observed
at 6-months was less pronounced after 12 months of
follow-up. Review of the deaths by the blinded, indepen-
dent CEC categorized 45% of the deaths in the placebo
group and 62% of the deaths in the lipo-ecraprost arm at 12
months as cardiovascular in nature.
In patients with rest pain on entry, including those in
either Fontaine stages III or IV, 24.3% of the placebo-
treated patients and 22.1% of the patients receiving
lipo-ecraprost were completely pain free after 6 months
Fig. Kaplan-Meier curves for amputation and mortality in the
intention-to-treat population. A, Shows the fraction of patients
without major amputation over the 6-month study period. Pa-
tients were censored from the analysis at the time of death or at the
time of last study contact if lost to follow up before the month 6
assessment. The number of patients remaining in the placebo and
lipo-ecraprost cohorts, respectively, were 190 and 189 on day 1,
172 and 159 on day 60, 155 and 147 on day 120, and 147 and 136
on day 180. B, Shows survival over the 12-months following the
first day of treatment. Patients were censored from the analysis at
time of last contact if they were lost to follow-up or had not
reached the 12-month assessment before study termination. The
number of patients remaining in the placebo and lipo-ecraprost
cohorts, respectively, were 190 and 189 on day 1, 170 and 164 on
day 100, 155 and 149 on day 200, 141 and 128 on day 300, and
84 and 82 on day 365.(Table IV). For patients with ulcerations or gangrene onentry, 24.5% of the placebo group and 23.2% of the lipo-
ecraprost group were ulcer free, with all wounds 100%
healed/epithelialized at 6 months (Table V). In these
analyses, patients who underwent amputation or died were
considered treatment failures (ie, were not pain- or ulcer-
free).
Reassessment of the qualifying hemodynamic measure-
ment (ankle pressure, toe pressure or TcPO2 for individual
patients) at 6 months demonstrated no effect of lipo-
ecraprost treatment (Table VI). Most patients had stable or
improved hemodynamics, although this cohort excluded
the patients who had undergone amputation or died before
the 6-month time point. Of note, 10% of the patients in the
placebo arm and 7.9% of patients in the lipo-ecraprost arm
had a revascularization procedure 6 months of random-
ization, despite the entry assessment that they were not
candidates for such procedures. These revascularized pa-
tients were included in the analysis of amputation rates
presented earlier. Four of 19 revascularized patients in the
placebo arm and three of 15 revascularized patients in the
lipo-ecraprost group underwent amputation6 months of
randomization. An additional patient in the lipo-ecraprost
group died during the 6-month study period without hav-
Table V. Pain relief and ulcer healing
Placebo (n) Lipo-ecraprost (n)
Pain on entry 181 181
Pain free at 6 months 44 (24.3%) 40 (22.1%)
Ulcers at entry 102 108
Ulcer free at 6 months 25 (24.5%) 25 (23.2%)
Patients with rest pain on entry, regardless of Fontaine stage were reassessed
for pain after 6months. Patients were asked to characterize their status at rest
as having no leg pain, pain in the left leg, pain in the right leg, or pain in both
legs. Patients with ulcers on entry (Fontaine stage IV) were assessed to
determine if they were ulcer free (all wounds completely healed) after 6
months. In both cohorts, patients who had died, undergone major ampu-
tation, or who were lost to follow-up were considered as having residual
disease (that is, not pain or ulcer free).
Table VI. Change in hemodynamics
Placebo
(n  190) (%)
Lipo-ecraprost
(n  189) (%)
Improved 33.7 32.8
Unchanged 16.3 27.0
Worsened 13.7 8.5
Patients underwent hemodynamic assessment after 6 months. Each patient’s
qualifying hemodynamic measurement (ankle pressure, toe pressure, or
TcPO2) at baseline was compared with the patient’s 6-month measurement.
A clinically meaningful change was prospectively defined as an increase or
decrease of 15% in the baseline measurement. Measurements within 15% of
the baseline value were categorized as unchanged. No 6-month measure-
ments were available for patients lost to follow-up, who had an amputation,
or who died. Patients were excluded if they underwent revascularization
before the 6-month assessment. Patients whose baseline hemodynamic value
was 0 were also excluded, as meaningful change could not be assessed
(36.3% of the placebo cohort and 31.7% of the lipo-ecraprost cohort).ing undergone an amputation.
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with the clinical status of the patients, the use of intrave-
nous study drug administration, and the vasoactive charac-
teristics of lipo-ecraprost. Patients on lipo-ecraprost expe-
rienced 7094 adverse events (202 serious), and 1594
adverse events (235 serious) were experienced in the pla-
cebo group. Common nonserious adverse events in the
lipo-ecraprost group included headache, pain, hypoten-
sion, tachycardia, vasodilation, diarrhea, and nausea and
vomiting, all of which were assessed as mild in severity by
the investigator in most instances. Despite the high fre-
quency of adverse events, patients were able to complete
placebo and lipo-ecraprost treatment regimens at similar
rates (see previous data). The CEC identified 38 cardiovas-
cular adverse events from 26 patients in the placebo group
and 49 cardiovascular events from 39 patients in the lipo-
ecraprost group. Of note, there were 11 cases of congestive
heart failure and 14 myocardial infarctions in the lipo-
ecraprost arm vs six of each in the placebo arm.
DISCUSSION
The current trial evaluated the efficacy of an intensive
prostaglandin regimen for the treatment of CLI. Each
intravenous treatment was at a near maximally tolerated
dose of 60 g, and treatment was maintained for up to 8
weeks. Consistent with consensus recommendations,20 a
clinically robust end point was selected that included major
amputation and death as treatment failures. Lipo-ecraprost
failed to reduce the primary composite endpoint, with
numerical trends at 6 months for death and amputation
each favoring placebo (Table IV).
Several lines of analysis support the conclusion that
lipo-ecraprost failed to modify the outcome in CLI:
● The study recruited a large number of subjects who
were well characterized at baseline.
● Strict hemodynamic criteria ensured that any symp-
toms suggestive of CLI were unambiguously associ-
ated with severe hemodynamic compromise.
● Although the placebo 6-month amputation rate of
13.0% was lower than might be expected for patients
without a revascularization option based on natural
history studies,3 this likely reflected selection biases for
clinical trial participation that excluded those patients
for whom amputation was seen as inevitable. The
placebo event rate was nonetheless sufficient to yield
an absolute number of events that facilitated meaning-
ful comparisons.
● The conclusion of “no benefit” from lipo-ecraprost
was independent of patient diabetes status, Fontaine
class, geographic distribution, or history of previous
revascularization. Similarly, limiting analysis only to
patients who received 30 doses of study medication
did not change the conclusions (data not shown).
● Finally, the eicosanoid was aggressively dosed (amount
per dose and duration of treatment) to maximize the
opportunity for drug benefit.Previous studies suggesting a benefit of prostaglandin E
have been relatively small or used an end point less clinically
meaningful than the one used here, or both. For example,
relief of pain, change in ulcer size, or relief from CLI are all
problematic end points, and consensus guidelines have
emphasized the importance of using amputation and death
as primary outcome measures.20 Nonetheless, secondary
analyses in the current study failed to identify any beneficial
effect of lipo-ecraprost on complete ulcer healing or com-
plete resolution of rest pain (Table V).
A major limitation in clinical trials in CLI is the subjec-
tive component of the decision to perform an amputation.
This limitation is amplified in trials of eicosanoids owing to
the vasodilating properties of the drugs and the associated
risk that the investigator will try to infer treatment arm assign-
ment of individual patients. The selection of a 6-month end
point mitigates these concerns to some degree, as a truly
irreversibly compromised limb would require amputation
eventually whatever the investigator’s biases might be with
respect to treatment. In contrast, the data from time to
amputation must be interpreted with more caution, as one
might anticipate that an investigator who suspected the
patient was receiving the active drug might delay amputa-
tion to see if the treatment would work.
The E-series prostaglandins can directly increase cyclic
adenosine monophosphate (cAMP) concentrations in some
tissues and increase systemic sympathetic tone in response
to the systemic vasodilation caused by the drug. Several
lines of evidence suggest that increased sympathetic tone or
increases in cAMP content may worsen outcomes in pa-
tients with cardiovascular disease.21,22 In this context, it is
important to note the trends (not statistically significant in
the current trials) towards increased cardiovascular events
and mortality associated with lipo-ecraprost use. In con-
trast, no adverse impact on mortality was observed in an
earlier trial with alprostadil--cyclodextrine treatment for
28 days in CLI patients.23
The current trial tested only a single dosage of lipo-
ecraprost. Although higher doses would likely not have
been tolerated, it is theoretically possible that lower doses
might be efficacious. In this context, it is important to note
that the phase II study done with a 10-g dose of lipo-
ecraprost suggested efficacy in a CLI population.19
CONCLUSION
Lipo-ecraprost treatment failed to improve the out-
come of patients with CLI who were not candidates for
revascularization. Given the potential for risk associated
with the use of vasoactive E-series prostaglandins in pa-
tients with cardiovascular disease, future use of high-dose,
systemically administered E-series prostaglandins in this
population cannot be recommended.
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